Polymerized degradable hyaluronan - a platform for stent coating with inherent inhibitory effects on neointimal formation in a porcine coronary model

被引：22

作者：

Heublein, B ^{[1
]}

Evagorou, EG ^{[1
]}

Rohde, R ^{[1
]}

Ohse, S ^{[1
]}

Meliss, RR ^{[1
]}

Barlach, S ^{[1
]}

Haverich, A ^{[1
]}

机构：

[1] Hannover Med Sch, Leibniz Res Labs Biotechnol & Artificial Organs, D-30659 Hannover, Germany

来源：

INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS | 2002年 / 25卷 / 12期

关键词：

hyaluronic acid; cross-linking; stent covering/coating; neointimal hyperplasia; porcine model; restenosis; interactive biomaterial;

D O I：

10.1177/039139880202501208

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

Biodegradable hyaluronan (hyaluronic acid, HA) made insoluble by self-cross-linking in the presence of N-(3-dimethylaminopropyl)-N'-ethyl carbodiimide (EDC) has been used to cover stents. The maximum polymer-mass on a 16-mm stainless steel stent is approximately 2 mg. During manual crimping and simulated application, the loss of polymerized HA is negligible. The insoluble HA coating has an advantageous inherent antiproliferative effect regarding neointimal formation after local vessel wall injury (overstretch model) and leads to a reduced inflammatory response compared to uncoated stainless-steel stents, used as control, in undiseased pig coronary arteries, over a follow-up period of four weeks. Thus, cross-linked HA stent coating warrants further research as an interactive degradable biomaterial with an inherent inhibitory effect on neointimal formation as a possible biomatrix for local drug delivery to reduce restenosis rate. (Int J Artif Organs 2002; 25: 1166-73).

引用

页码：1166 / 1173

页数：8

共 29 条

[1] Inhibition of neointima formation after experimental coronary artery stenting -: A new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost [J].

Alt, E ;

Haehnel, I ;

Beilharz, C ;

Prietzel, K ;

Preter, D ;

Stemberger, A ;

Fliedner, T ;

Erhardt, W ;

Schömig, A .

CIRCULATION, 2000, 101 (12) :1453-1458

[2]

BURNS JW, 1991, Patent No. 5017229

[3]

Cook AD, 1997, J BIOMED MATER RES, V35, P513

[4] Pathology of acute and chronic coronary stenting in humans [J].

Farb, A ;

Sangiorgi, G ;

Carter, AJ ;

Walley, VM ;

Edwards, WD ;

Schwartz, RS ;

Virmani, R .

CIRCULATION, 1999, 99 (01) :44-52

[5] Acute and chronic tissue response to coronary stent implantation:: Pathologic findings in human specimen [J].

Grewe, PH ;

Deneke, T ;

Machraoui, A ;

Barmeyer, J ;

Müller, KM .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (01) :157-163

[6]

Heldman AW, 2001, CIRCULATION, V103, P2289

[7]

Heublein B, 1998, J INVASIVE CARDIOL, V10, P255

[8]

JAM M, 1996, J CLIN INVEST, V97, P596

[9]

KIMURA T, 2001, CIRCULATION, V104, P928

[10] AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44 [J].

Lamb, RF ;

Hennigan, RF ;

Turnbull, K ;

Katsanakis, KD ;

MacKenzie, ED ;

Birnie, GD ;

Ozanne, BW .

MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (02) :963-976

← 1 2 3 →